Immunotherapy Coverage from Every Angle
Advertisement
Advertisement

Recent News

SITC 2022: Is Immunotherapy Feasible for Patients Living With HIV and NSCLC?
SITC 2022: Avelumab-Based Combination Therapy for Advanced Urothelial Carcinoma
SITC 2022: Cellular Research May Lead to the Next Generation of Therapies for Myeloma
Neoadjuvant Cemiplimab-rwlc Treatment of Cutaneous Squamous Cell Carcinoma
SITC 2022: Neoantigen-Specific Antibody Responses in Metastatic Triple-Negative Breast Cancer
SITC 2022: First-Line Antigen Presenting Cell Activator Plus Pembrolizumab Under Study in NSCLC
SITC 2022: Ongoing Study of Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma
SITC 2022: Can ctDNA Help to Predict Therapeutic Outcomes in Patients With NSCLC?
SITC 2022: Identifying Markers for Grade 3 Toxicities in Patients With LBCL Treated With Axicabtagene Ciloleucel
AASLD 2022: Using MRI to Predict Response to Combination Immunotherapy for Liver Cancer
FDA Approves Combination Immunotherapy Regimen Plus Chemotherapy for Metastatic Lung Cancer
SITC 2022: Use of Cell-Free DNA Monitoring to Predict Outcomes With Immunotherapy in NSCLC
SITC 2022: Antigen-Specific Memory CD8-Positive T Cells Target BCMA to Treat Multiple Myeloma
SITC 2022: Anakinra Prophylaxis and Toxicity of Axicabtagene Ciloleucel in Resistant LBCL
SITC 2022: Neoadjuvant Combination of Radiotherapy and Pembrolizumab in Triple-Negative Breast Cancer
SITC 2022: Phase II Study of Vudalimab for Metastatic Castration-Resistant Prostate Cancer
SITC 2022: Phase II Trial Update on Vaccine Plus Pembrolizumab in Resistant Bladder Cancer
ASTRO 2022: Stereotactic Ablative Radiotherapy Plus Durvalumab for Early-Stage NSCLC
Cempilimab-rwlc Plus Chemotherapy Receives FDA Approval in NSCLC
ASTRO 2022: Salvage Radiotherapy for Advanced B-Cell NHL After CAR T-Cell Therapy
FDA Brief: Bispecific Antibody Receives Breakthrough Therapy Designation in Resistant Myeloma
Neoadjuvant Use of Ipilimumab Plus Nivolumab and Chemoradiotherapy for NSCLC
ASTRO 2022: Can Adding Radiotherapy to Immunotherapy Improve Outcomes in Advanced Liver Cancer?
SLAMF7 Antigen and Myeloma: Therapeutic Target for Antibody-Based and Cellular Immunotherapy?
ASTRO 2022: Can Bridging Radiotherapy Reduce Toxicity of Immunotherapy for Resistant B-Cell Lymphoma?
Daratumumab-Based Chemoimmunotherapy for Multiple Myeloma: Focus on Advanced Renal Failure
ASTRO 2022: 2-Year KEYNOTE-799 Update on Pembrolizumab Plus Chemoradiotherapy in Stage III NSCLC
FDA Brief: Teclistamab-cqyv Granted Accelerated Approval in Resistant Myeloma
CD38-CAR Natural Killer Cells: Potential Immunotherapy Target in Multiple Myeloma?
Durvalumab Plus Tremelimumab Receives FDA Approval in Treatment of Advanced Liver Cancer
Tisagenlecleucel Infusion in Lymphoma: Focus on Coagulation and Fibrinolytic Parameters
FDA Brief: Fast Track Designation Granted to STAT3 Inhibitor in Liver Cancer
SOHO 2022: How Does CAR T-Cell Therapy Measure Up to ASCT in Advanced DLBCL?
Overall Survival Update on Durvalumab Plus Chemotherapy for Advanced Biliary Tract Cancer
Shorter Duration of Treatment With Nivolumab Plus Ipilimumab in Advanced NSCLC
FDA Brief: Priority Review for Sacituzumab Govitecan in HR-Positive, HER2-Negative Metastatic Breast Cancer
Adjuvant Nivolumab in Resected Merkel Cell Carcinoma: Interim Results From Phase II Trial
SOHO 2022: Update From CARTITUDE-2 of Ciltacabtagene Autoleucel in Multiple Myeloma
RATIONALE-301: Final Analysis Shows Benefit of Tislelizumab in Hepatocellular Carcinoma
Unresectable Hepatocellular Carcinoma: Phase III Results Support Novel Doublet
SOHO 2022: Clinical Overview of CD20/CD3 Bispecific Antibodies in B-Cell Lymphoma
Blocking CD73 With Oleclumab in Combination Therapy for Triple-Negative Breast Cancer
Phase III LEAP-002 Study of Lenvatinib Alone or With Pembrolizumab in Advanced Liver Cancer
BCMA-Targeted CAR T-Cell Therapy for Older Patients With Multiple Myeloma
ASCO Quality 2022: Long-Term Quality-of-Life Impact of Lisocabtagene Maraleucel in LBCL
Are Baseline Ocular Conditions Affected by Belantamab Mafodotin Treatment in Myeloma?
ESMO 2022: Biomarker Analyses Focus on Resistance to T-DXd in Metastatic Breast Cancer
ESMO 2022: Novel Bispecific Antibody Plus Chemotherapy Under Study in NSCLC
Advanced Urothelial Carcinoma: Combination of Soluble EphB4-Human Serum Albumin Plus Pembrolizumab
FDA Approves Durvalumab in Combination Regimen for Advanced or Metastatic Biliary Tract Cancer
Immunotherapy for Advanced Biliary Tract Cancer: Tumor Mutational Burden as a Predictive Biomarker?
Durvalumab With and Without Tremelimumab in Unresectable Hepatocellular Carcinoma


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.